New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
09:21 EDTBIIB, ALKSAlkermes issued patent for fumarate pro-drug, says Citigroup
Citigroup notes that Alkermes (ALKS) was issued a United States patent for its pro-drug of mono-methyl fumarate, the active ingredient in Biogen's (BIIB) Tecfidera. Citi views the patent as supporting the regulatory potential of ALKS 8700, and notes the drug is a long-term threat to Tecfidera. The firm says Phase 1 data expected by year-end 2014 could be meaningful and keeps a Buy rating on Alkermes with a $60 price target.
News For ALKS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 15, 2015
07:29 EDTBIIBOutlook for Biogen trials positive , says RBC Capital
Subscribe for More Information
January 14, 2015
07:05 EDTBIIBIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information
06:32 EDTALKSAlkermes price target raised to $85 from $72 at Citigroup
Subscribe for More Information
January 13, 2015
13:09 EDTBIIBBiogen CEO says company has strengthened R&D, to stay active in M&A
Subscribe for More Information
07:42 EDTALKSJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use